Project Grant R43MH133495

Award Date 9/1/23
Completion Date 2/28/25
Dollars Obligated $487K
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to advance the identification and understanding of circadian delay in children with Attention-Deficit/Hyperactivity Disorder (ADHD). The overarching objectives are to characterize circadian function among 250 ADHD children aged 6-9 using gold-standard assessments, examine associations between circadian dysfunction, ADHD clinical presentation, and...
The federal Project Grant award R43DA062460 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $399,739 grant supports Attune Neurosciences, Inc., a for-profit organization, to develop a head-worn low-intensity focused ultrasound (LIFU) device for enhancing sleep in individuals with substance use disorder (SUD), including opioid use disorder (OUD). The key objectives of the 9-month project are to: 1) reconfigure...
This Project Grant award of $826,902 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports research to investigate the dynamic relationships between physical activity, sleep, and circadian rhythms with heterogeneity in clinical symptoms and neurobehavioral functioning in children with Attention-Deficit/Hyperactivity Disorder (ADHD). The research, led by the Hugo W. Moser Research Institute at Kennedy Krieger, Inc., will...
The National Institute of Child Health and Human Development (NICHD) awarded a $295,907 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to Liberating Technologies Inc. (LTI) to develop a prototype "Unintrusive Pediatric Logging Orthosis Analytic Device (UPLOAD)." The goal is to create a commercially viable, unobtrusive remote monitoring system for pediatric orthotics that can improve compliance tracking. Key features include long battery life, low...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,602,357 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to KDH Research & Communication, Inc., a woman-owned small business located in Atlanta, GA. The grant funds the development and evaluation of the "Personalized Approach to Habits-Sleep" (PATH-S) mobile app, which aims to improve sleep duration and asthma symptoms for Black teenagers aged 14-17 with asthma. The PATH-S app will...
The National Science Foundation awarded a $256,000 Small Business Innovation Research Phase I Project Grant to Lumostech, Inc. under the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a smart sleep mask and mobile application to improve sleep for adolescents. The one-year project will apply light flash technology delivered through a sleep mask to advance teenagers' circadian phases without disrupting daytime activities. Cognitive behavioral therapy delivered via mobile...
This federal Project Grant award from the National Institute of Mental Health (NIMH) under CFDA Program 93.242 (Mental Health Research Grants) provides funding to Nurelm Inc. to develop and test the LEMURDX system. LEMURDX is a software platform that uses machine learning and wearable device sensors to objectively measure hyperactivity in children with ADHD. The $615,908 award over 3 years will be used to refine the LEMURDX product to enhance ease of use for clinical researchers, and to test the...
This Project Grant award in the amount of $181,234 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will fund research to study the impact of early psychostimulant exposure on sleep neurophysiology and circadian rhythms in animal models of Attention-Deficit/Hyperactivity Disorder (ADHD). The research aims to break down the complex relationship between ADHD, psychostimulant medications like methylphenidate, and their...
This $1,309,500 Project Grant awarded by the National Institutes of Health (NIH) under the Trans-NIH Research Support (CFDA 93.310) program supports the development of a novel digital psychiatry diagnostic framework that utilizes crowdsourcing algorithms to improve the specificity of machine learning models in distinguishing between autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in adolescents. The key products and services to be delivered under this 3-year...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $408,400 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and assess a wearable magnetoencephalography (MEG) system for use in children. The key objectives are to: 1) Develop and optimize an age-appropriate, movement...

RESTEAZE: A NOVEL WEARABLE DEVICE AND MOBILE APPLICATION TO IMPROVE THE DIAGNOSIS AND MANAGEMENT OF RESTLESS LEGS SYNDROME IN PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER - PROJECT ABSTRACT MILLIONS OF PEDIATRIC PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) SUFFER FROM SLEEP DISTURBANCES THAT SIGNIFICANTLY DEGRADE THEIR QUALITY OF LIFE AND AMPLIFIES THE HEAVY EMOTIONAL AND FINANCIAL BURDEN ON CAREGIVERS. RESTLESS LEGS SYNDROME (RLS) IS A LIKELY (AND TREATABLE) FACTOR FOR THE SLEEP DISTURBANCE IN THESE PATIENTS. ORAL IRON THERAPY HAS BEEN SHOWN TO IMPROVE BOTH SLEEP AND ADHD SYMPTOMS IN CHILDREN. HOWEVER, RLS IS CURRENTLY DIFFICULT TO DIAGNOSE, PARTICULARLY IN PEDIATRIC PATIENTS WITH ADHD. THE DIAGNOSIS IS MADE CLINICALLY WITH SUBJECTIVE, PATIENT REPORTS AND THE SYMPTOMS THEMSELVES ARE VARIABLE ACROSS INDIVIDUALS. THUS, PATIENTS WITH ADHD WHO MAY ALREADY HAVE DIFFICULTY WITH VERBAL EXPRESSION ARE ESPECIALLY VULNERABLE TO BEING MISDIAGNOSED. RESTEAZE IS AN ANKLE-WORN WEARABLE TECHNOLOGY AND MOBILE APPLICATION DEVELOPED BY TANZEN MEDICAL INC. TO MEASURE LEG MOVEMENTS DURING SLEEP THAT ARE HIGHLY RELATED TO RLS AND CAN SERVE AS AN OBJECTIVE BIOMARKER OF THE CONDITION. THE DEVICE IS INDUSTRIALLY DESIGNED TO BE COMFORTABLY WORN BY THE PATIENT AND WASHABLE TO PERMIT EXTENDED, NIGHTLY USE. THE MOBILE APPLICATION IS EASY TO USE BY THE PATIENT (OR CAREGIVER) TO INTERACT WITH AND STORE DATA FROM THE DEVICE. THE READ-OUT PROVIDED TO THE CLINICIAN PROVIDES CLEAR, ACTIONABLE INFORMATION THAT QUANTIFIES THE PATIENTS' LEG MOVEMENTS DURING SLEEP IN REFERENCE TO AMERICAN ACADEMY OF SLEEP MEDICINE STANDARDS. IN SUM, RESTEAZE DIRECTLY ADDRESSES A SIGNIFICANT UNMET MEDICAL NEED BY PROVIDING A TECHNOLOGY THAT CAN SUBSTANTIALLY IMPROVE THE DIAGNOSIS AND SUBSEQUENT MANAGEMENT OF RLS IN PEDIATRIC PATIENTS WITH ADHD. THE USE OF THIS TECHNOLOGY IS EXPECTED TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS WITH ADHD AND THEIR CAREGIVERS BY DIRECTLY ADDRESSING THEIR SLEEP DISTURBANCE.

Posted 8/30/23, 12:00 AM